Preoperative radiotherapy (RT) followed by surgery is widely accepted in the treatment of locally advanced rectal cancer (LARC). This study aimed to estimate at the population-based level the impact of preoperative RT on overall survival (OS) and cancer-specific survival (CSS) in LARCs diagnosed in Southern Switzerland between 1996 and 2007. All patients with LARC were selected from the Ticino Cancer Registry database. Patients were categorized according to the first administered treatment: preoperative radiotherapy (RT) followed by surgery (RT+) versus surgery (RT -). Clinical-pathological characteristics and 5-year OS and CSS were analysed. Among 384 patients with LARC, 54% underwent preoperative RT, occurring more frequently in the mid-distal part of the rectum compared with the RT -group (74.8 vs. 29.8%, respectively). Both 5-year OS and CSS significantly improved in RT+ patients (OS: 68 vs. 54%, respectively; CSS: 71 vs. 63%, respectively). The adjusted hazard ratio for all death was equal to 0.66 (95% confidence interval: 0.46; 0.97); similarly, the hazard ratio for cancer-specific death was 0.63 (95% confidence interval: 0.39; 0.99). These observational population-based results, after controlling for most important diagnostic and clinical prognostic factors, confirm the benefit of preoperative RT of LARC, even if the magnitude seems greater than expected in clinical trials results. Additional studies are needed, particularly with regard to the possible effect of standardized staging procedure and multidisciplinary discussion on patient outcome.
Introduction
Modern multimodal treatment of rectal cancer, associated with multidisciplinary management, has resulted in high control rates, improvements in survival rates and quality of life (Glimelius and Oliveira, 2008; Van Cutsem et al., 2008; Valentini et al., 2009) . In particular, the last decade has brought enormous advances in surgical techniques (e.g. total mesorectal excision is now endorsed by all surgeons), chemotherapy (CT) regimens, development of new targeting drugs such as epidermal growth factor receptor and angiogenesis inhibitors and preoperative therapeutic approaches. Considering neoadjuvant treatments, the results of major published randomized clinical trials (RCTs) remained inconsistent and the overall assessment of the preoperative treatment effect was difficult to evaluate until the end of the 1990s. The Swedish Rectal Cancer Trial (SRCT) demonstrated a significant relative survival benefit after a long-term follow-up in the group of patients treated with preoperative radiotherapy (RT) followed by surgery (No authors listed, 1997; Folkesson et al., 2005) . Moreover, the SRCT results were compared with the Swedish Cancer Registry findings; authors concluded that the SRCT results were reliable, as the sample of patients included in the SRCT study was representative of the general population, assessing therefore the evidence for the generalizability of the results (Dahlberg et al., 1998 (Dahlberg et al., , 1999 . A recent meta-analysis of 14 RCTs showed that preoperative RT significantly improves 5-year overall survival (OS) and cancer-specific survival (CSS) versus surgery alone in resectable rectal cancers, with a greater benefit in the advanced tumour stages (i.e. Dukes B and C) than in the early stages (Dukes A) (Camma et al., 2000) . In another systematic review of 22 trials, the authors found that RT, before or after surgery, essentially reduced the risk of local recurrences and moderately reduced deaths from rectal cancer; however, the benefits detected with preoperative treatment were significantly greater than those with postoperative RT (Colorectal Cancer Collaborative Group, 2001) . Similarly, recent data from a German trial showed that preoperative radio(chemo)therapy is superior to postoperative therapy in resectable rectal cancers, in terms of both better local control and less toxicity (Sauer et al., 2004) . In contrast, a more recent systematic overview showed late adverse effects because of preoperative RT, although these effects are fewer in recent studies, which generally used smaller irradiated volumes and better irradiation techniques (Birgisson et al., 2007) .
Population-based Cancer Registry data are essential to describe and reflect real world and routine care as well as to assess the management of a disease in daily practice and those treatments that are routinely prescribed and/or effective in all patient groups. The information obtained from the few population-based epidemiological overviews on this issue is limited and incomplete (Martling et al., 2001; Martijn et al., 2003; Kerr et al., 2005; Van Cutsem et al., 2008) . Seeing that data from population-based studies are lacking and data coming from RCTs did not show consistent results on survival data, we therefore conducted the present population-based study to analyse the impact of preoperative RT on OS and CSS in association with the main clinical-pathological features, in patients diagnosed with locally advanced rectal cancer (LARC) between 1996 and 2007 in the South of Switzerland.
Methods

Patient selection
All patients with invasive rectal cancer diagnosed in the South of Switzerland between 1996 and 2007 were selected from the files of the population-based Ticino Cancer Registry. The Registry is located in the Southern Italian-speaking part of Switzerland, within the regional Institute of Pathology, which has provided all rectal cancer histological diagnoses included in this study.
With regard to the Registry collection of data, most cases are usually notified by the Institute of Pathology. Additional cases are actively collected in public and private hospitals (discharge letters), RT and oncology centres, oncologists, general practitioners and other Swiss Cancer Registries (Bordoni et al., 2009) . Tumour topography and morphology are classified using the International Classification of Diseases for Oncology-III and the WHO Classification of Tumours of the Digestive System (Fritz et al., 2000; Hamilton and Aaltonen, 2000) . All information is actively collected and registered by the Registry Staff according to the International Agency for Research on Cancer guidelines and the European Network of Cancer Registries recommendations (Tyczynski et al., 2003; Parkin et al., 2004) .
The first quality inspection and plausibility tests are automatically performed by the computer system during the data entry phase. In addition, quality controls on multiple primaries, comparability, validity and consistency of data are carried out by means of the International Agency for Research on Cancer checks programme (Ferlay et al., 2005) . Case completeness is assessed through the method reported in Bullard et al. and through standard quality indicators (Bullard et al., 2000; Montanaro et al., 2006; Curado et al., 2007; Bordoni et al., 2009) .
Patients were categorized into two subgroups according to the first treatment they received straight after diagnosis: preoperative RT with or without neoadjuvant CT (identified in this study as 'RT+') followed by surgery; and surgery as a primary intervention (identified as 'RT -'). Surgery was defined as transabdominal resection. Because recent studies have demonstrated that the addition of CT to preoperative RT significantly improves tumour response but not OS, we included both patients receiving RT in combination with CT and those receiving only RT in the RT+ group (Ceelen et al., 2006; Martijn and Vulto, 2007) .
LARCs were defined as advanced extended tumours (T3/ T4) and/or tumours with lymph node involvement (N1/ N2) and with no distant metastasis (M0). The clinical tumour staging (cTNM) of preoperative ultrasound sonography and/or MRI and/or computerized axial tomography was used to define LARC in RT+ patients, whereas pathologic staging (pTNM) of surgical resection specimens was used for RT -patients (Greene et al., 2002) .
Essential clinical-pathological characteristics were analysed, such as patient age, sex, tumour localization, lymph node status, histological grade, histological type and treatment procedures. Tumour site was classified according to the extended International Classification of Diseases for Oncology version proposed by Wagner as follows: C20.91 = distal rectum (4-7.5 cm from the dental line), C20.92 = mid rectum (7.5-12 cm), C20.93 = proximal rectum (12-16 cm) and C20.90 = rectum not otherwise specified (Wagner, 1993) . Cancers of the colon, rectosigmoid junction and anus were excluded. Histological grade was evaluated according to WHO criteria (Hamilton and Aaltonen, 2000) . With regard to the histological type, mucinous adenocarcinomas, which are considered more aggressive than regular carcinomas and harder to successfully treat, were compared with all other adenocarcinomas (carcinoid, neuroendocrine tumours and lymphoma of rectum were excluded) (Fritz et al., 2000; Hamilton and Aaltonen, 2000) . Surgical resections were considered as complete (R0) when the proximal and distal margins were not invaded by residual tumour (> 1 mm).
Radiotherapy treatment
Patients received RT at the Radiation Oncology Unit of the Oncology Institute of Southern Switzerland. Preoperative RT, as the first therapeutic approach, consisted of external pelvic irradiation with a 3D conformal technique (3D-EBRT) in three or four fields (box technique). For patients treated with neo-adjuvantconcurrent RT-CT, the total irradiation dose was 44-45 Gy with a standard fractionation of 1.8-2.0 Gy daily and five fractions weekly (long-course RT). In this case, the concurrent CT was 5-fluorouracil or Capecitabine.
Patients treated with preoperative RT alone received either a total dose of 44-45 Gy with the same standard fractionation (long-course RT) or a total dose of 25 Gy with a hypofractionation regimen of 5 Gy daily and five fractions weekly (short-course RT).
Statistical analysis
Median values are provided for quantitative variables, whereas proportions represent qualitative variables. Differences between RT+ and RT -groups were evaluated through Student's t-test for continuous variables, whereas the w 2 or Fisher's exact test was used for discrete variables. The Wilcoxon -Mann -Whitney test was performed for ordinal variables (Armitage et al., 2002) .
Survival analysis was carried out for the subgroup of patients with a 5-year complete follow up, that is, referring to the incidence period 1996-2005. The active follow up (31 December 2010) consisted of systematic checks of patient vital status through a record-linkage procedure between the local Cancer Registry database and the regional Office of Population Registry Rosters. To extract and increase the quality and the reliability of cancer-specific causes of death we constructed a specific variable (death of rectal cancer, considered for the analysis of CCS; death of another cancer; death of other causes not related to cancer) derived from the following sources of information: Swiss Federal Office of Statistics, which provides to the Registry the single death certificates with cancer diagnosis and the list of death cancer codes; public and private hospitals, which systematically send medical documents, reports and discharge letters; physicians, who fill in ad-hoc questionnaires provided by the Registry. Five-year OS and CSS curves, which took into account only deaths due to malignancies of the rectum and censored those individuals dying of other causes than rectal tumours, were assessed by the Kaplan-Meier method. The log-rank test was used to detect statistically significant differences in survival (Armitage et al., 2002) . Simultaneous assessment of prognostic factors was performed through the multivariate analysis of the Cox proportional-hazards regression model. The magnitude of the effect of each independent covariate, adjusted for main clinical-pathological variables, such as patient age, was estimated by the hazard ratio (HR) for all deaths and cancer-specific deaths with the corresponding 95% confidence intervals (95% CI) (Armitage et al., 2002) .
Statistical significance was determined at P < 0.05. SAS System V9.1 was used for the statistical analyses (SAS Institute Inc., Cary, North Carolina, USA).
Results
Between 1996 and 2007, 677 incident rectal adenocarcinomas, histologically confirmed at the diagnosis, were identified at the South Switzerland Cancer Registry. Of the 677 rectal cases, 400 were LARCs, of which 16 cases were excluded from the analysis because the patients received only neoadjuvant CT (without neoadjuvant RT) before surgery, or only palliative treatment, or refused any treatment, or information about treatments was not available. The total number of patients with LARC included in this study is 384, whose clinical-pathological characteristics are summarized in Table 1 . Fifty-four per cent of patients were treated with neoadjuvant radio(chemo)therapy before surgery (RT+), and the remaining 46% directly underwent surgical intervention (RT -). In the RT+ group, 82% also received neoadjuvant CT in combination with RT before surgery.
The remaining 277 patients with non-LARC were excluded by further detailed analysis, not being the target of the study: 130 (46.9%) patients were stage I, 101 (36.5%) patients were stage IV and 46 (16.6%) cases were unclassified.
Patient characteristics of locally advanced rectal cancers
The M : F ratio was equal to 1.39. The median age was 67 years, and RT+ patients were significantly younger than RT -patients (65 vs. 72 years, respectively; P < 0.001). This difference was also confirmed when patients were stratified according to specific age groups (P < 0.001): a higher percentage of patients younger than 70 years was detected in the RT+ group (66.0 vs. 41.0%, respectively), whereas RT -showed the highest proportion of patients aged 80 years or over (28.1 vs. 7.3%, respectively).
Tumour characteristics of locally advanced rectal cancers
Tumour localization differed significantly between the two groups (P < 0.001): 50.5% of RT+ patients presented with distal rectum cancer, whereas less than 20.0% had a proximal lesion. In contrast, only 18.0% of the RT -group had distal rectal cancer, whereas the majority of patients (60.7%) had a proximal tumour. With regard to the lymph node status, RT+ patients were more likely to be diagnosed with negative lymph nodes (55.8%), whereas RT -patients were equally distributed between negative and positive lymph nodes. There was a significant difference in tumour extension distribution (P = 0.001): more cases were diagnosed as T3-T4 in the RT+ group compared with RT -patients (97.1 and 88.2%, respectively). The median number of examined lymph nodes was higher when neoadjuvant RT was not performed (7 in RT+ and 10 in RT -patients). No significant difference was detected when patients were stratified according to histological grade, but a higher proportion of poorly differentiated cases was observed in patients not treated with neoadjuvant RT (15.7 vs. 13.6%, respectively). Considering histological type, mucinous adenocarcinomas were more frequent in the RT -group, although this was not statistically confirmed (9.0 vs. 6.3%, respectively).
Surgical and adjuvant treatments of locally advanced rectal cancers
A similar proportion of complete resections (R0) was observed in the two groups (97.6% in RT+ vs. 95.5% in RT -; P = 0.264). With regard to the postoperative treatments, CT was more frequently administered to RT+ patients (43.2 vs. 39.3%, respectively; P = 0.442).
Survival analysis of locally advanced rectal cancers
The univariate analysis showed a significant difference between the RT+ and RT -groups in both 5-year OS (68 vs. 54%, respectively; P = 0.0026) and CCS (71 vs. 63%, respectively; P = 0.0468) (Fig. 1) . Such significant differences in survival between the RT+ and RTgroups were confirmed in the subgroups with positive lymph nodes (OS: 58 vs. 41%, respectively; P = 0.0199; CCS: 63 vs. 49%, respectively; P = 0.0457) (Fig. 2) , T3-T4 (OS: 69 vs. 51%, respectively; P = 0.0004; CCS: 72 vs. 61%, respectively; P = 0.0115) (Fig. 3) , distal rectum (OS: 66 vs. 42%, respectively; P = 0.0044; CCS: 67 vs. 48%, respectively; P = 0.0157) (Fig. 4) , and wellto-moderately differentiated cancers (OS: 72 vs. 57%, respectively; P = 0.0034; CCS: 75 vs. 66%, respectively; P = 0.0403) (data not shown). In all analyses, the RT -group showed the worst survival probability. 
Discussion
In the last two decades, a debate with regard to the therapeutic approaches to rectal cancer was launched and included neoadjuvant versus postoperative radio (chemo)therapy and surgical technique improvements (Camma et al., 2000; Colorectal Cancer Collaborative Group, 2001; Sauer et al., 2004; Sebag-Montefiore et al., 2009) . Clinical trials showed that patients with rectal cancer undergoing preoperative RT were characterized by better local control, less toxicity and fewer local recurrences than patients undergoing surgery alone or surgery followed by adjuvant treatments, particularly in the case of LARCs (Dukes B and C) (Colorectal Cancer Collaborative Group, 2001; Sauer et al., 2004; Folkesson et al., 2005; Birgisson et al., 2007) . More recently an improvement of OS and CSS has been observed (No authors listed, 1997; Camma et al., 2000) . In addition to clinical studies, in which elderly patients are generally under-enrolled, population-based studies are the best way to provide regular feedback to healthcare workers and decision makers about the management of a disease in daily and routine practice in all patient groups (Peppercorn et al., 2004; Jennens et al., 2006; Kalata et al., 2009) . With regard to the LARCs, even if neoadjuvant RT is recommended in several guidelines, population-based survival data are still lacking.
In this study, RT+ patients showed a significantly better 5-year OS and CSS compared with RT -patients (OS: 68 vs. 54%, respectively; CSS: 71 vs. 63%, respectively). Interestingly, the effect increased in positive lymph nodes, T3-T4 and distal rectal cancers, showing the best benefit for patients undergoing preoperative RT. The multivariate Cox model analysis confirmed the significant and independent impact of preoperative radio (chemo)therapy on OS and CSS.
Considering CSS, it is known that death statistics are not always as trustworthy and reliable as we would like. However the consultation of different sources of information (Swiss Federal Office, public and private hospitals, Five-year overall survival (OS) and cancer-specific survival (CSS) in locally advanced rectal cancers with positive lymph nodes, diagnosed in Southern Switzerland, according to the first administered treatment: preoperative radiotherapy (RT+) versus surgery (RT -).
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physicians) allowed us to correctly identify the rectal cancer-specific cause of death.
Consistent with previous studies, preoperative RT was delivered more frequently to patients with distal and mid-rectal cancers; moreover, a significant difference in CSS was detected between the RT+ and RT -groups in the distal rectal subsite, confirming the particular importance of such treatment for this high-risk localization (Sebag-Montefiore, 2006; Martling et al., 2009) .
The high proportion of patients with R0 (96.6%, OS) is indicative of a good curative surgical approach, and this also applied to tumours that were not resectable before neoadjuvant RT (97.6 and 95.5% in the RT+ and RTgroups, respectively). However, because it was difficult to exactly distinguish between total mesorectal excision and low anterior resection, we considered them together as transabdominal surgery. In the multivariate model, we used the lymph node status, tumour localization and residual tumour to assess the effect of the type of surgery. It is noteworthy that the mean number of examined lymph nodes of the RT -group is in line with that expected by international recommendations (National Comprehensive Cancer Network, 2008; Mekenkamp et al., 2009 ). In the last period of the study (2002) (2003) (2004) (2005) (2006) (2007) , this value increased to 13.2 in RT -patients, confirming the increasing trend in lymph node detection reported by others (Mekenkamp et al., 2009) .
In this study we observed survival difference between RT+ and RT -even bigger than expected in clinical trial results, both in the univariate and multivariate analysis adjusted by the most important prognostic factors.
A possible source of bias could be represented by the use of cTNM in RT+ and pTNM in RT -patients to define LARCs. Unfortunately, we could not use the clinical stage for all RT -patients, because it was not available for all cases. However for those RT -patients who had cTNM, we checked the consistency between cTNM and pTNM, finding a correspondence. We, thus, hypothesized that there would not have been a substantial difference between cTNM and pTNM for the RT -group. However, the observed frequency of complete cTNM in the two considered study groups could have caused a selection-to-treat bias, influencing the survival results. Moreover, the diagnostic modalities used to determine the clinical TNM staging (sonography vs. MRI) varied during the considered period. According to a recent metaanalysis, MRI seems more useful to stage T3-T4 rectal cancers, whereas sonography is more accurate for T1-T2 rectal cancers (Bipat et al., 2004; LeBlanc, 2007) . Thus, considering that the used preoperative approach (particularly the pretreatment staging process) was not Five-year overall survival (OS) and cancer-specific survival (CSS) in T3-T4 locally advanced rectal cancers, diagnosed in Southern Switzerland, according to the first administered treatment: preoperative radiotherapy (RT+) versus surgery (RT -). Five-year overall survival (OS) and cancer-specific survival (CSS) in locally advanced rectal cancers localized in the distal part of rectum, diagnosed in Southern Switzerland, according to the first administered treatment: preoperative radiotherapy (RT+) versus surgery (RT -).
introduced in the multivariate analysis, we could hypothesize that it could play a role in the observed additional survival benefit.
In addition, information on multidisciplinary case discussion approaches and follow-up schemes after the surgery (although surveillance bias) needs further in-depth analysis. Another minor limitation could be the lack of information about the assigned RT regimens (shortcourse vs. long-course with or without CT), although today the available literature does not support enough a possible influence of different RT regimens on survival outcome (Bujko et al., 2006; Pettersson et al., 2010) . In contrast, considering the available literature, it is less probable that comorbidity has influenced our results, particularly the CSS observation (Lemmens et al., 2005; Vulto et al., 2006; Iversen et al., 2009 ). Lemmens et al. (2005) found that a previous malignancy was the most important comorbidity leading to a less frequent use of RT, this factor was included in our multivariate regression model.
In conclusion the study confirms the benefit of preoperative RT for LACR patients also in the real world, and at the same time shows an even greater than expected benefit of preoperative RT compared with clinical trials results, both in terms of OS and CSS, particularly in patients with distal cancers as well as in patients with positive lymph nodes and T3-T4 tumours. Additional in-depth analysis is needed, particularly of factors influencing the decision to treat patients with neoadjuvant RT versus primary surgical resection, followed by a possible effect on patient outcome. HRs are adjusted for all other variables. b Tumour localization was significant only for cancer-specific analysis. c Tumour extension at diagnosis was significant only for overall analysis.
